Drug Trial Radar · NCT03303079
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
Last checked: Nov 20, 2026Latest source record: Jun 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
571
Actual
Start
Dec 19, 2017
Primary completion
Nov 30, 2019
Study completion Nov 30, 2019
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- First posted
- Oct 5, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 \[monthly TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3 months\] compared with placebo for preventive treatment in Chronic Migraine patients
Conditions
- Migraine
Interventions
TEV-48125Drug
TEV-48125 will be subcutaneously administered once monthly for 3 months.
TEV-48125 or placeboDrug
TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
PlaceboDrug
Placebo will be subcutaneously administered once monthly for 3 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity During the 12-week Period After the First Dose of Investigational Medicinal Product (IMP)Time frame: Baseline, 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Saitama Medical University Hospital
Iruma, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.